Original Publication Date: 1 May, 2017
Publication / Source: FUTURE SCIENCE OA
Authors: Eleftheria A Anastasopoulou & Ioannis F Voutsas
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host . Although the rationale of cancer vaccination studies seems to be promising, therapeutic efficacy is rather limited [2,3]. One reason that could account for that is the inappropriate clinical trial design and patient selection, rather than the vaccine itself .